Oslo, 18 August 2023: The board of directors of Navamedic ASA (the "Company"),
has today, on 18 August 2023, in accordance with the authorisation granted to it
by the general meeting on 1 June 2023, resolved to increase the Company's share
capital by NOK 92,500 by issuance of 125,000 new shares, each with a nominal
value of NOK 0.74, in order to facilitate the settlement of exercise of 125,000
share options. The exercise prices are NOK 14.46 per share for 25,000 of the new
shares and NOK 19.00 per share for 100,000 of the new shares. The new shares are
subject to a 12 month lock-up period.

Following the registration of the share capital increase with the Norwegian
Register of Business Enterprises (Nw.: Foretaksregisteret), the new share
capital of the Company will be NOK 12,841,054.98, divided into 17,352,777
shares, each with a nominal value of NOK 0.74. The share capital increase will
be registered with the Norwegian Register of Business Enterprises as soon as
practically possible after the share contribution has been fully paid.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

About Navamedic ASA:

Navamedic ASA is a Nordic full-service provider of high-quality products to
hospitals and through pharmacies. Navamedic meets the specific needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in the UK and
Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA).

For more information, please visit www.navamedic.com.

This information is subject of the disclosure requirements pursuant to section5
-12 of the Norwegian Securities Trading Act.